Japanese drugmaker Takeda has suspended dosing in phase 2 trials of its orexin agonist TAK-994, saying it had encountered a "safety signal" in the study.
Harmony Biosciences has scored an expanded use for its Wakix narcolepsy drug to include cataplexy – a symptom of the sleep disorder that can cause total body collapse.
The FDA has approved Jazz Pharmaceuticals’ sleep disorder drug Xywav, to treat daytime sleepiness in patients with narcolepsy, offering a regime with less sodium than standard therapy.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
